Obesity And Gut Microbiota PdfBy Rickey H. In and pdf 25.11.2020 at 15:38 9 min read
File Name: obesity and gut microbiota .zip
Probiotics are now recognized for several health benefits and they have been recommended as a complementary therapeutic agent for metabolic disorders. Obesity is an altered health condition, which is a resultant of irregular energy intake and energy balance, changes in gut microbiota, and improper diet with the influence of genetic makeup and environmental factors.
- Gut Microbiota and Obesity
- Gut microbiota: a new path to treat obesity
- A Review on Role of Microbiome in Obesity and Antiobesity Properties of Probiotic Supplements
Gut Microbiota and Obesity
Malnutrition through excessive food consumption is a worldwide pandemic. Changes in lifestyle, diet and physical activity have resulted in an exponential increase in the number of obese people around the world. Multiple factors influence the development of this disease, and recently it has been suggested that gut microbiota GM plays an important role in nutrient absorption and energy regulation of individuals, thus affecting their nutritional status. It has been proven that gut microbiota is different in individuals with a normal nutritional status compared to those who are obese. Therefore, to study bacterial populations that make up the microbiota and to understand how prebiotics and probiotics affect the increase of these bacteria has become a promising alternative to treat obesity. This chapter looks at defining the established relationship between probiotics, prebiotics and gut microbiota that develop in obese people and people of normal weight, with the aim of providing future dietary recommendations to treat this medical condition. Oral Health by Using Probiotic Products.
Gut microbiota: a new path to treat obesity
Metabolic diseases can change the gut microbiota composition and function, and pathogenic bacteria contribute to the development of metabolic disorders. Polyphenols may act in the gut microbiota to favor the increase of beneficial bacteria and hamper the increase of pathogenic bacteria. In addition, the microbiota may act on polyphenols to increase their bioavailability. This two-way interactions between polyphenols and the gut microbiota could affect human metabolism and reduce cardiometabolic risk. Despite the possible benefits of polyphenols for human health through modulating the microbiome, studies are scarce, and present several limitations.
Between 1, and 1, bacterial species have potential to colonise the human gastro-intestinal GI tract, with each individual harbouring around different species 1. The composition of the gut microbiota has received attention as an etiological factor in the development of obesity. It is sensitive to dietary changes and able to alter composition within hours in both animals and humans Independently of diet, the gut microbiota is able to influence host inflammatory responses. The bacterial components of Gram-negative bacteria, such as lipopolysaccharide LPS , trigger innate immune responses in the host which can lead to weight gain 6.
The evidences from animal models suggest that it is possible that the microbiota of obese subjects has higher capacity to harvest energy from the diet providing.
A Review on Role of Microbiome in Obesity and Antiobesity Properties of Probiotic Supplements
Concern about health risks associated with rising obesity has become nearly universal, with the mean body mass index BMI and the prevalence of obese and overweight individuals increasing substantially worldwide during the previous three decades. Unfortunately, prevention and treatment of obesity and related complications have proven complex, and successful strategies to tackle this pathology remain limited. Epidemiological studies have highlighted potential environmental exposures, including diet, energy expenditure, early life influences, sleep deprivation, endocrine disruptors, chronic inflammation, and microbiome status, contributing to higher risk of obesity Franks and McCarthy, Among these, the microbiome has received extensive attention during the previous decade.
chapter and author info
Boxes indicate interquartile ranges IQR , and whiskers the range of the data expanding up to 1. FMT indicates fecal microbiome transfer. Secondary Outcomes at 6, 12, and 26 Weeks Postintervention. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published.
Box , Kuwait City, Kuwait. Obesity and its associated complications like type 2 diabetes T2D are reaching epidemic stages. Increased food intake and lack of exercise are two main contributing factors. Recent work has been highlighting an increasingly more important role of gut microbiota in metabolic disorders. This review summarizes key discoveries during the past decade that established the role of gut microbiota in the development of obesity and diabetes. It will look at the role of key metabolites mainly the short chain fatty acids SCFA that are produced by gut microbiota and how they impact key metabolic pathways such as insulin signalling, incretin production as well as inflammation.
The journal's aim is to publish articles focused on basic, clinic care and translational research that seeks to prevent rather than treat the complications of endstage liver disease. The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two receding years. CiteScore measures average citations received per document published.
These things obviously have a very significant effect on our host physiology. Since Bomhof and his wife Tara had their first son in June, the funding will be particularly welcome in allowing him to stay focused. Like many researchers in his field, the questions that Bomhof wants to answer revolve around the growing problem of obesity in our society.
Its pages are open to the members of the Association, as well as to all members of the medical community interested in using this forum to publish their articles in accordance with the journal editorial policies. The principal aim of the journal is to publish original work in the broad field of Gastroenterology, as well as to provide information on the specialty and related areas that is up-to-date and relevant. The scientific works include the areas of Clinical, Endoscopic, Surgical, and Pediatric Gastroenterology, along with related disciplines. The journal accepts original articles, scientific letters, review articles, clinical guidelines, consensuses, editorials, letters to the Editors, brief communications, and clinical images in Gastroenterology in Spanish and English for their publication.
The pathophysiology of obesity and obesity-related diseases such as type 2 diabetes mellitus T2DM is complex and driven by many factors. One of the most recently identified factors in development of these metabolic pathologies is the gut microbiota. The introduction of affordable, high-throughput sequencing technologies has substantially expanded our understanding of the role of the gut microbiome in modulation of host metabolism and cardio metabolic disease development. Nevertheless, evidence for a role of the gut microbiome as a causal, driving factor in disease development mainly originates from studies in mouse models: data showing causality in humans are scarce. In this review, we will discuss the quality of evidence supporting a causal role for the gut microbiome in the development of obesity and diabetes, in particular T2DM, in humans.